(Q36549221)

14 August 2017

7 references

13 March 2019

14 March 2019

24 March 2019

3 April 2019

29 May 2020

13 September 2020

25 January 2021

Taxol: an important new drug in the management of epithelial ovarian cancer (English)

1 reference

phytogenic antineoplastic agents

14 August 2017

2 references

13 September 2020

25 January 2021

5 references

13 March 2019

14 March 2019

24 March 2019

3 April 2019

1 reference

13 September 2020

1 reference

25 January 2021

1 reference

M. Markman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1687343

29 October 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1687343

29 October 2022

publication date

1 November 1991

1 reference

PMCID

2589424

full work available at URL

14 August 2017

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/1687343/pdf/?tool=EBI

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1687343

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/1687343/?tool=EBI

29 October 2022

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1687343

https://europepmc.org/articles/PMC2589424

29 October 2022

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1687343

https://europepmc.org/articles/PMC2589424?pdf=render

29 October 2022

file format

Portable Document Format

online access status

open access

content deliverer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1687343

Yale Journal of Biology and Medicine

29 October 2022

published in

7 references

14 August 2017

13 March 2019

14 March 2019

24 March 2019

3 April 2019

13 September 2020

25 January 2021

64

1 reference

14 August 2017

6

1 reference

14 August 2017

583-590

1 reference

Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2589424

Chemotherapy of drug-resistant ovarian cancer: a Southwest Oncology Group Study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2589424

Phase I study of taxol administered as a short i.v. infusion daily for 5 days.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2589424

Phase I trial of taxol in patients with advanced cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2589424

Phase I trial of taxol given as a 3-hour infusion every 21 days

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2589424

Intraperitoneal therapy in the management of ovarian carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2589424

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2589424

Taxol: a novel investigational antimicrotubule agent

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2589424

Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2589424

Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2589424

Comparison of antitumor activity of standard and investigational drugs at equivalent granulocyte-macrophage colony-forming cell inhibitory concentrations in the adhesive tumor cell culture system: an in vitro method of screening new drugs

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2589424

Second-line chemotherapy of stage III-IV ovarian carcinoma: a randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent disease after doxorubicin and cisplatin.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2589424

Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2589424

Phase I clinical and pharmacokinetic study of taxol.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2589424

Therapeutic response to taxol of six human tumors xenografted into nude mice.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2589424

Phase I and pharmacodynamic study of taxol in refractory acute leukemias.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2589424

Hypersensitivity reactions from taxol

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2589424

Phase I study of taxol using a 5-day intermittent schedule

28 June 2018

1 reference

12 December 2020

Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration

1 reference

12 December 2020

Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma

1 reference

12 December 2020

1 reference

12 December 2020

A phase II trial of taxol in metastatic melanoma

1 reference

12 December 2020

Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds

1 reference

12 December 2020

Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms

1 reference

12 December 2020

Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study

1 reference

12 December 2020

Antineoplastic activity of two taxol derivatives on an ovarian tumor xenografted into nude mice

1 reference

12 December 2020

Identifiers

PMCID

2589424

1 reference

14 August 2017

1 reference

PMCID

2589424